Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Oncotarget
|
June 4, 2016
ATM protein is deficient in over 40% of lung adenocarcinomas
Liza C Villaruz, Helen Jones, Sanja Dacic, et al.
Molecular Cancer Therapeutics
|
October 25, 2018
Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Haihong Zhong, Cui Chen, Ravinder Tammali, et al.
British Journal of Cancer
|
December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
Claudia Winkler, Joshua Armenia, Gemma N Jones, et al.
Science Signaling
|
September 15, 2016
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML
Isabel Morgado-Palacin, Amanda Day, Matilde Murga, et al.
EMBO Molecular Medicine
|
July 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, et al.
Molecular Cancer Therapeutics
|
May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways
Jonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Molecular Cancer Therapeutics
|
March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Michael D Oberst, Catherine Augé, Chad Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim, Simon A Smith, Peter Mortimer, et al.
British Journal of Cancer
|
November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Sophie Archer, Phillip M Brailey, Minjung Song, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Oncotarget
|
June 4, 2016
ATM protein is deficient in over 40% of lung adenocarcinomas
Liza C Villaruz, Helen Jones, Sanja Dacic, et al.
Molecular Cancer Therapeutics
|
October 25, 2018
Improved Therapeutic Window in <i>BRCA</i>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Haihong Zhong, Cui Chen, Ravinder Tammali, et al.
British Journal of Cancer
|
December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
Claudia Winkler, Joshua Armenia, Gemma N Jones, et al.
Science Signaling
|
September 15, 2016
Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML
Isabel Morgado-Palacin, Amanda Day, Matilde Murga, et al.
EMBO Molecular Medicine
|
July 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio, et al.
Molecular Cancer Therapeutics
|
May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways
Jonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Molecular Cancer Therapeutics
|
March 17, 2018
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
Michael D Oberst, Catherine Augé, Chad Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2021
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
Seung Tae Kim, Simon A Smith, Peter Mortimer, et al.
British Journal of Cancer
|
November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Sophie Archer, Phillip M Brailey, Minjung Song, et al.
Page
of 5